Report Information More information from: https ://www.wis eguyreports .com/reports /495858
Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Pipeline Review, H1 2016 Report / Search Code: WGR495858
Price
1-user P DF : $ 3500.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 7000.0
Enterprise P DF : $ 10500.0
Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Pipeline Review, H1 2016’, provides in depth analys is on Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) targeted pipeline therapeutics . The report provides comprehens ive information on the Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11), targeted therapeutics , complete with analys is by indications , s tage of development, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) targeted therapeutics development and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape for Proteinas eActivated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - The report reviews Proteinas e-Activated Receptor 2 (Coagulation Factor II ReceptorLike 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) targeted therapeutics under development by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved in Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin
Receptor-Like 1 or F2RL1 or GPR11) targeted therapeutics and enlis ts all their major and minor projects - The report as s es s es Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) targeted therapeutics bas ed on mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news and deals related to Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) targeted therapeutics Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand the targeted therapy areas and indications for Proteinas eActivated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Identify the us e of drugs for target identification and drug repurpos ing - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Proteinas eActivated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) development lands cape - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope Contents:
Table of Contents Table of Contents 2 Lis t of Tables 4 Lis t of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) Overview 6 Therapeutics Development 7 Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Products under Development by Stage of Development 7 Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Products under Development by Therapy Area 8 Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Products under Development by Indication 9 Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Pipeline Products Glance 10 Early Stage Products 10 Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Products under Development by Companies 11 Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Products under Development by Univers ities /Ins titutes 13 Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Therapeutics As s es s ment 15 As s es s ment by Monotherapy/Combination Products 15 As s es s ment by Mechanis m of Action 16 As s es s ment by Molecule Type 17 Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Companies Involved in Therapeutics Development 19 Hadas it Medical Res earch Services & Development Ltd 19 Ups her-Smith Laboratories , Inc. 20 Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Drug Profiles 21 Drugs to Antagonize Proteas e Activated Receptor-2 for Pancreatitis Pain - Drug Profile 21 Product Des cription 21
Mechanis m Of Action 21 R& D Progres s 21 P-2pal18S - Drug Profile 22 Product Des cription 22 Mechanis m Of Action 22 R& D Progres s 22 Peptide to Antagonize PAR-1 and PAR-2 for Oncology - Drug Profile 23 Product Des cription 23 Mechanis m Of Action 23 R& D Progres s 23 Peptides for Breas t Cancer - Drug Profile 24 Product Des cription 24 Mechanis m Of Action 24 R& D Progres s 24 PZ -235 - Drug Profile 25 Product Des cription 25 Mechanis m Of Action 25 R& D Progres s 25 Small Molecules to Antagonize PAR-2 for Atopic Dermatitis , Inflammatory Bowel Dis eas e and Ulcerative Colitis - Drug Profile 26 Product Des cription 26 Mechanis m Of Action 26 R& D Progres s 26 Proteinas e-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Dormant Projects 27 Appendix 28 Methodology 28 Coverage 28 Secondary Res earch 28 Primary Res earch 28 Expert Panel Validation 28 Contact Us 28 Dis claimer 29 Lis t of Tables Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analys is by Early Stage Products , H1 2016 10 Number of Products under Development by Companies , H1 2016 11 Products under Development by Companies , H1 2016 12 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 13 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 14 As s es s ment by Monotherapy/Combination Products , H1 2016 15 Number of Products by Stage and Mechanis m of Action, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 18 Pipeline by Hadas it Medical Res earch Services & Development Ltd, H1 2016 19 Pipeline by Ups her-Smith Laboratories , Inc., H1 2016 20 Dormant Projects , H1 2016 27 Lis t of Figures Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analys is by Early Stage Products , H1 2016 10 As s es s ment by Monotherapy/Combination Products , H1 2016 15 Number of Products by Stage and Mechanis m of Actions , H1 2016 16 Number of Products by Molecule Types , H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 17
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349